Table 1.
Listing of location and details of current clinical trials being completed to investigate the potential role of bone marrow-derived progenitor cell therapeutics for the treatment of ischemic stroke.
| Location of Study | Study Design | Deliver Route | Sample Size | Cell Type | Inclusion Criteria | Outcomes | Time Window |
|---|---|---|---|---|---|---|---|
| United States (The University of Texas in Houston) |
Single arm | IV | 10 | Autologous BMMCs | - MCA stroke - 18–80 yo - NIHSS 6 to 20 |
Safety and feasibility | 24 to 72 hrs |
|
| |||||||
| Taiwan (The China Medical University Hospital) |
Randomized (cell infusion versus conventional treatment) | IC | 30 | Autologous peripheral blood CD34+ cells | - Stable deficits hemiplegia - 35–70 yo - NIHSS 9 to 20 |
Safety and efficacy | 6 months to 5 years |
|
| |||||||
| Spain (Hospital Universitario Central de Asturias) |
Single arm | IA | 20 | Autologous CD34+ bone marrow cells | - MCA stroke - 18–80 yo - NIHSS ≥ 8 |
Safety | 5 to 9 days |
|
| |||||||
| France (University Hospital of Grenoble) |
Randomized (Control versus 2 treatment groups) | IV | 30 | Autologous bone marrow derived progenitor cells | - Carotid territory stroke - 18–65 yo - NIHSS > 2 |
Feasibility and tolerability | 6 weeks |
|
| |||||||
| United Kingdom (Imperial College London) | Single arm | IA | 10 | Autologous CD34+ bone marrow cells | - MCA stroke - 30–80 yo - Severe stroke conforming to the TACS phenotype (weakness, homonymous hemianopia and a focal cognitive deficit |
Safety and tolerability | 7 days |
|
| |||||||
| Brazil (Federal University of Rio de Janeiro) |
2 arms (non randomized: 10 IA/5IV) | IV/IA | 15 | Autologous BMMCs | - MCA stroke - 18–75 yo - NIHSS 4 to 20 |
Safety | 3 hrs to 90 days |
IV: intravenous; IA: intra-arterial; IC: intracerebral; BMMC: bone marrow mononuclear cells; MCA: middle cerebral artery; NIHSS: National Institutes of Health Stroke Scale; TACS: total anterior circulation stroke.